| abstract |
Disclosed herein is a biomarker or biomarker gene (eg, EP300, MLL2, BCL-) to stratify patients with hematological malignancies such as DLBCL for treatment. 2, RB1, LRP1B, PIM1, TSC2, TNFRSF11A, SMAD4, PAX5, CARD11, ACTG2, LOR, GAPT, CCND2, SELL, GEN1, HDAC9, CD79B, MYD88, and ROS1), or using biomarker gene expression levels Methods, systems, compositions, arrays, and kits for and for administering TEC inhibitors to selected patients. Also disclosed herein are biomarkers, biomarkers, to monitor patients during the treatment of hematological malignancies such as DLBCL or FL, or to optimize treatment plans involving TEC inhibitors Methods, systems, compositions, arrays, and kits for utilizing gene or biomarker gene expression levels. [Selection] Figure 2 |